China Pioneer Pharma Holdings
Market Cap
HK$1.3b
Last Updated
2021/01/16 10:17 UTC
Data Sources
Company Financials
Executive Summary
China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People’s Republic of China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet and fair value.
Similar Companies
Share Price & News
How has China Pioneer Pharma Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1345 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 1345's weekly volatility has decreased from 19% to 7% over the past year.
Market Performance
7 Day Return
10.6%
1345
-3.3%
HK Healthcare
2.2%
HK Market
1 Year Return
14.3%
1345
-18.2%
HK Healthcare
7.2%
HK Market
Return vs Industry: 1345 exceeded the Hong Kong Healthcare industry which returned -17.9% over the past year.
Return vs Market: 1345 exceeded the Hong Kong Market which returned 7.5% over the past year.
Shareholder returns
| 1345 | Industry | Market | |
|---|---|---|---|
| 7 Day | 10.6% | -3.3% | 2.2% |
| 30 Day | 2.0% | -0.2% | 8.4% |
| 90 Day | -1.0% | 14.9% | 15.6% |
| 1 Year | 36.6%14.3% | -16.0%-18.2% | 11.4%7.2% |
| 3 Year | -51.4%-59.4% | -42.8%-46.4% | -3.4%-13.5% |
| 5 Year | -22.8%-43.2% | -29.9%-32.0% | 65.4%37.4% |
Long-Term Price Volatility Vs. Market
How volatile is China Pioneer Pharma Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
9 hours ago | Simply Wall St
Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?2 weeks ago | Simply Wall St
China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance SheetValuation
Is China Pioneer Pharma Holdings undervalued compared to its fair value and its price relative to the market?
26.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1345 (HK$1.04) is trading below our estimate of fair value (HK$1.42)
Significantly Below Fair Value: 1345 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1345 is poor value based on its PE Ratio (28.7x) compared to the HK Healthcare industry average (20.6x).
PE vs Market: 1345 is poor value based on its PE Ratio (28.7x) compared to the Hong Kong market (11.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1345's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1345 is good value based on its PB Ratio (1.1x) compared to the HK Healthcare industry average (1.5x).
Next Steps
Future Growth
How is China Pioneer Pharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
25.3%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Pioneer Pharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine whether China Pioneer Pharma Holdings is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- China Pioneer Pharma Holdings competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has China Pioneer Pharma Holdings performed over the past 5 years?
-19.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1345 has high quality earnings.
Growing Profit Margin: 1345's current net profit margins (2.8%) are lower than last year (4.9%).
Past Earnings Growth Analysis
Earnings Trend: 1345's earnings have declined by 19.7% per year over the past 5 years.
Accelerating Growth: 1345's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1345 had negative earnings growth (-41.5%) over the past year, making it difficult to compare to the Healthcare industry average (-9.1%).
Return on Equity
High ROE: 1345's Return on Equity (3.8%) is considered low.
Next Steps
Financial Health
How is China Pioneer Pharma Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 1345's short term assets (CN¥952.8M) exceed its short term liabilities (CN¥281.2M).
Long Term Liabilities: 1345's short term assets (CN¥952.8M) exceed its long term liabilities (CN¥8.0M).
Debt to Equity History and Analysis
Debt Level: 1345's debt to equity ratio (4.6%) is considered satisfactory.
Reducing Debt: 1345's debt to equity ratio has reduced from 78.8% to 4.6% over the past 5 years.
Debt Coverage: 1345's debt is not well covered by operating cash flow (4%).
Interest Coverage: 1345 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is China Pioneer Pharma Holdings's current dividend yield, its reliability and sustainability?
7.36%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1345's dividend (7.36%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.13%).
High Dividend: 1345's dividend (7.36%) is in the top 25% of dividend payers in the Hong Kong market (6.66%)
Stability and Growth of Payments
Stable Dividend: 1345 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 1345 has only been paying a dividend for 7 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (316.8%), 1345's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Chunyi Luo (51 yo)
2yrs
Tenure
CN¥869,000
Compensation
Mr. Chunyi Luo has been CEO and Director at China Pioneer Pharma Holdings Ltd since January 22, 2019. He has extensive experience in corporate management and banking. Prior to joining the Group, he had ser...
CEO Compensation Analysis
Compensation vs Market: Chunyi's total compensation ($USD134.11K) is below average for companies of similar size in the Hong Kong market ($USD305.97K).
Compensation vs Earnings: Insufficient data to compare Chunyi's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | CN¥1.74m | 2.14% CN¥ 27.2m | |
| CEO & Executive Director | 2yrs | CN¥869.00k | no data | |
| Chief Financial Officer | 4.08yrs | no data | no data | |
| Executive Director | 0.83yr | no data | no data | |
| Company Secretary | 1.83yrs | no data | no data | |
| General Manager of Easyhaler & Neutrophase Business Unit | 6.33yrs | no data | no data |
2.0yrs
Average Tenure
50yo
Average Age
Experienced Management: 1345's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | CN¥1.74m | 2.14% CN¥ 27.2m | |
| CEO & Executive Director | 2yrs | CN¥869.00k | no data | |
| Executive Director | 0.83yr | no data | no data | |
| Non-Executive Director | 7.25yrs | CN¥216.00k | no data | |
| Independent & Non-Executive Director | 7.25yrs | CN¥315.00k | no data | |
| Independent Non-Executive Director | 2yrs | no data | no data | |
| Non-Executive Director | 0.083yr | no data | no data | |
| Independent Non-Executive Director | 0.083yr | no data | no data |
2.0yrs
Average Tenure
57yo
Average Age
Experienced Board: 1345's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 1345 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
China Pioneer Pharma Holdings Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: China Pioneer Pharma Holdings Limited
- Ticker: 1345
- Exchange: SEHK
- Founded: 1996
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: HK$1.271b
- Shares outstanding: 1.22b
- Website: https://www.pioneer-pharma.com
Number of Employees
Location
- China Pioneer Pharma Holdings Limited
- No.15, Lane 88 Wuwei Road
- Putuo District
- Shanghai
- Shanghai Province
- 200331
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1345 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Nov 2013 |
| 14P | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Nov 2013 |
Biography
China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People’s Republic of China. It has a portfoli...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/16 10:17 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.